Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Clinical trials including cardiovascular outcomes studies have not demonstrated increased thrombotic events compared to placebo
Lilys Mounjaro (tirzepatide) is the first dual agonist to market with its 2022 approval
Other Ingredients: purified water
Defined continuation criteria: for example, NICE recommends at least 5% weight loss after 12 weeks of treatment at the maintenance dose as a threshold for continued prescribing
Medical weight loss involves the use of FDA-approved medications such as Semaglutide (marketed as Ozempic or Wegovy) and Tirzepatide (marketed as Mounjaro or Zepbound) to help patients achieve and maintain a healthy weight
US$ 25.04
US$ 23.58
US$ 24.27
US$ 29.35
US$ 21.89
US$ 25.54
US$ 28.16
US$ 20.68
